It can be clinically challenging to distinguish dry age-related macular degeneration (AMD) from AMD-mimicking dystrophies, and sometimes misdiagnosis occurs. With upcoming therapies for dry AMD it is important to exclude patients with a different retinal disease from clinical trials. In this study we evaluated the occurrence of AMD-mimicking dystrophies in an AMD cohort.
Whole-exome sequencing (WES) was performed in 218 patients with intermediate AMD or geographic atrophy secondary to AMD and 133 control individuals. WES data was analyzed for rare variants in 19 genes associated with autosomal dominant and recessive macular dystrophies mimicking AMD. In three (1.4%) of 218 cases we identified a pathogenic heterozygous variant (PRPH2 c.424C > T; p.R142W) causal for autosomal dominant central areolar choroidal dystrophy (CACD). Phenotypically, these patients all presented with geographic atrophy. In 12 (5.5%) of 218 cases we identified a heterozygous variant of unknown clinical significance, but predicted to be highly deleterious, in genes previously associated with autosomal dominant macular dystrophies. The distinction between AMD and AMD-mimicking dystrophies, such as CACD, can be challenging based on fundus examination alone. Genetic screening for genes associated with macular dystrophies, especially PRPH2, can be beneficial to help identify AMD-mimicking dystrophies.
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| INTRODUCTION
Age-related macular degeneration (AMD) is a common progressive retinal disorder affecting the elderly. 1 The early stages of AMD are characterized by drusen accumulation in the macula, and as disease progresses two types of advanced AMD can be distinguished: geographic atrophy (GA) and choroidal neovascularization. 2 Currently, no curative treatment exists for the early and atrophic stages of AMD, which affect the majority of patients (80%-90%). However, therapies targeting AMD disease pathways are currently being evaluated in clinical trials. 3, 4 In order for clinical trials to be successful, it is crucial to select patients that will most probably benefit from the treatment. However, sometimes it is clinically challenging to distinguish AMD from inherited macular dystrophies. [5] [6] [7] Especially when a patient presents at older age and GA has already developed, it can be challenging to distinguish AMD from GA secondary to other macular diseases and potentially patients might be misdiagnosed. Before inclusion of patients in clinical trials for dry AMD, it may therefore be useful to perform genetic testing to exclude AMD-mimicking dystrophies. In this study, we evaluated the occurrence of rare genetic variants associated with autosomal dominant or autosomal 
| Whole-exome sequencing
Whole-exome sequencing (WES) was performed as previously described. 9 WES data were analyzed for rare variants in 19 genes associated previously with autosomal dominant and recessive macular dystrophies mimicking AMD as described by Saksens et al 5 and
RetNet, the Retinal Information Network (Supporting Information Figure 1 unknown clinical significance in the BEST1, ELOVL4, FSCN2, IMPG1, OTX2, PRDM13, PROM1 or RP1L1 gene ( Figure S1 ). We cannot rule out the possibility that these variants might be disease-causing. Therefore, one might consider to exclude patients carrying variants in genes associated with autosomal dominant macular dystrophies from clinical trials, in particular if the disease phenotype matches previously reported disease characteristics of these dystrophies.
| Variants in genes associated with autosomal recessive retinal dystrophies
None of our cases carried homozygous or two heterozygous deleterious variants in genes associated with autosomal recessive macular dystrophies. However, 13 (6.0%) out of 218 cases carried a single heterozygous variant, previously described to be pathogenic in the literature or in public archives, in the ABCA4, ABCC6, MFSD8 or PROM1 gene ( Table 2 , Supporting Information Figure S2 ). Eight variants showed comparable MAFs with population reference panels, while seven variants were not detected in the 133 control individuals.
It has been suggested that carriers of a single ABCA4 variant are at increased risk of developing AMD compared to non-carriers, 18, 19 although a more recent study described that monoallelic ABCA4 carriers do not result in retinal changes. 20 In this study, we identified seven (3.2%) of 218 cases that carried a heterozygous ABCA4 variant previously reported to be pathogenic, compared to only one (0.8%) of 133 control individuals carrying a heterozygous pathogenic ABCA4
variant. Larger studies are needed to evaluate the hypothesis that carriers of heterozygous variants associated with autosomal recessive macular dystrophies might be at increased risk for AMD development.
The frequency of ABCA4 variants in our control individuals is, however, lower than expected based on population frequencies, and could also be coincidentally low.
| Clinical implications
It is increasingly important to correctly diagnose patients with macular degeneration with respect to inclusion in clinical trials and for future treatment. No curative treatment is currently available for dry AMD, although multiple clinical trials are ongoing. 4 For clinical trials and future therapies for AMD, it is important to identify those patients that will benefit most probably from the treatment and to exclude 
